Continuous Addition of Adenosine with a Micropump System Improves Warm Whole Blood Cardioplegia
Background: Micropump additive systems allow for continuous modification of cardioplegia composition during heart surgery. Although the use of such systems in warm heart surgery is theoretically desirable, the role of the systems has been clinically limited by coronary vasoreactivity with higher potassium concentration and unreliable mechanical arrest at lower potassium concentration. Adenosine, a potent coronary vasodilator and arresting agent, has the potential to reduce the potassium concentration required for arrest and to improve distribution of cardioplegia. However, clinical use of adenosine has been limited by a short half-life in blood and difficulty in titrating the dose. This study tested the hypothesis that continuous addition of adenosine with an in-line linear micropump system would facilitate whole blood hyperkalemic perfusion for cardiac surgery.
Methods: Canine hearts (n = 9) were randomized to 20 minutes of arrest with whole blood cardioplegia or cardioplegia with adenosine at either low (0.5 3M) or high (8 3M) concentration. Potassium was supplemented at an arresting dose (24 mEq/L) for 5 minutes and then at a maintenance dose (6 mEq/L) for an additional 15 minutes. Coronary flow was held constant (4 mL/kg per minute), and aortic root pressure was measured. Myocardial performance was assessed by measurement of the end-diastolic pressure to stroke volume relationship at constant afterload. Myocardial tissue perfusion was evaluated with colored microspheres.
Results: During the initial period of high-concentration potassium arrest, coronary resistance rose progressively regardless of adenosine addition. Coronary resistance remained elevated during the period of low potassium perfusion, except when high-concentration adenosine was added. With addition of 8 3M adenosine, coronary resistance returned to baseline, and left ventricular endocardial perfusion was augmented. Electromechanical quiescence improved with adenosine perfusion and was complete with high-dose adenosine addition. Function was preserved in all hearts.
Conclusion: Use of a modern micropump system allowed for continuous addition of adenosine and potassium to whole blood cardioplegia. Adenosine minimized potassium-induced coronary vasoconstriction and improved endocardial perfusion and mechanical quiescence. These findings supported addition of adenosine to the perfusate during warm whole blood cardioplegia.
Berne RM. 1980. The role of adenosine in the regulation of coronary blood flow. Circ Res 47:807-17.nBolling SF, Bies LE, Gallagher KP, et al. 1989. Enhanced myocardial protection with adenosine. Ann Thorac Surg 47:809-15.nCannon MB, Vine AJ, Kantor HL, et al. 1994. Warm and cold blood cardioplegia: comparison of myocardial function and metabolism using 31p magnetic resonance spectroscopy. Circulation 90:II328-38.nClaude RE. 1983. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 93:21-6.nCohen G, Feder-Elituv R, Iazetta J, et al. 1998. Phase 2 studies of adenosine cardioplegia. Circulation 98:II225-33.nDaggett WM, Nugent GC, Carr PW, et al. 1967. Influence of vagal stimulation on ventricular contractility, O consumption and coronary flow. Am J Physiol 212:8-18.nDiMarco JP, Sellers TD, Berne RM, et al. 1983. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 68:1254-63.nDobson JG Jr. 1983. Adenosine reduces catecholamine contractile responses in oxygenated and hypoxic atria. Am J Physiol 245:H468-74.nEly SW, Mentzer RM Jr, Lasley RD, et al. 1985. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 90:549-56.nFollette D, Fey K, Becker H, et al. 1980. Superiority of blood cardioplegia over asanguinous cardioplegia: an experimental and clinical study. Chir Forum Exp Klin Forsch 279-83.nFremes SE, Levy SL, Christakis GT, et al. 1996. Phase I human trial of adenosine-potassium cardioplegia. Circulation 94:370-5.nGeffin AG, O'Keefe DD, Denenberg AG, et al. 1987. Microsphere reference flow samples during systemic flow adjustment. Am J Physiol 252:H851-6.nGuyton RA, Gott JP. 1995. A critical evaluation of warm blood cardioplegia. In: Salerno TA, ed. Warm heart surgery. London: Edward Arnold Press. p 168-77.nHe GW, Yang CQ. 1996. Hyperkalemia alters endothelium-dependent relaxation through non-nitric oxide and noncyclooxygenase pathway: a mechanism for coronary dysfunction due to cardioplegia. Ann Thorac Surg 61:1394-9.nHearse DJ, Stewart DA, Braimbridge MV. 1975. Hypothermic arrest and potassium arrest, metabolic and myocardial protection during elective cardiac arrest. Circ Res 36:481-9.nMaddali MM, Reddy JD, Krishnaswami S. 2000. Adenosine as an adjunct to inducing rapid asystole during cardioplegic arrest. Indian Heart J 52:434-7.nMenasche P. 1996. Blood cardioplegia: do we still need to dilute? Ann Thorac Surg 62:957-60.nMorrison RR, Talkuder MAH, Ledent C, et al. 2002. Cardiac effects of adenosine A receptor knockout hearts: uncovering A receptors. Am J Physiol 282:H437-44.nMoser GH, Schrader J, Deuce A. 1989. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 256:C799-806.nOlsson RA, Davis CJ, Khouri EM, Patterson RE. 1976. Evidence for an adenosine receptor on the surface of dog coronary myocytes. Circ Res 39:93-8.nRescigno G, Nataf P, Raffoul R. 1998. Continuous warm blood cardioplegia pitfalls. Heart Surg Forum 1:142-5.nSatyanarayana PV, Rao PS, Rao KM, et al. 1992. Continuous normothermic cardioplegia: simplified delivery circuit. Ann Thorac Surg 54:810.nSchrader J, Haddy FJ, Gerlach E. 1977. Release of adenosine, inosine and hypoxanthine from the isolated guinea pig heart during hypoxia, flow-autoregulation and reactive hyperemia. Pflugers Arch 369:1-6.nSchubert T, Vetter H, Owen P, et al. 1989. Adenosine cardioplegia. J Thorac Cardiovasc Surg 98:1057-65.nSoderback U, Sollevi A, Fred Holm BB. 1987. The disappearance of adenosine from blood and platelet suspension in relation to platelet cyclic AMP content. Acta Physiol Scand 129:189-94.nTorchiana DF, Vine AJ, Titus JS, et al. 2000. The temperature dependence of cardioplegic distribution in the canine heart. Ann Thorac Surg 70:614-20.nTyers GF, Todd GJ, Niebauer IM. 1975. The mechanism of myocardial damage following potassium citrate (Melrose) cardioplegia. Surgery 78:45-53.nWillem de Jong J, van de Meer P, van Loon H, et al. 1990. Adenosine as adjunct to potassium cardioplegia: effect on function, energy metabolism, and electrophysiology. J Thorac Cardiovasc Surg 100:445-54.nWilson RF, Wyche K, Christensen BV, et al. 1990. Effects of adenosine on human coronary arterial circulation. Circulation 82:1596-606.nBelardinelli L, Giles WR, West A. 1988. Ionic mechanisms of adenosine actions in pacemaker cells from the rabbit heart. J Physiol 405:615-33.nHearse DJ, Stewart DA, Braimbridge MV. 1978. Myocardial protection during ischemic cardiac arrest: possible deleterious effects of glucose and mannitol in coronary infusates. J Thorac Cardiovasc Surg 36:320-7.nLasley RD, Konyn PJ, Hegge JO, et al. 1995. The effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am J Physiol 269:H1460-6.nLatouff OM, Jabr AK, Spence PA. 1995. Pitfalls in warm oxygenated blood cardioplegia. In: Salerno TA, ed. Warm heart surgery. London: Edward Arnold Press. p 134-9.nLedingham S, Katayama O, Lachno D, et al. 1990. Beneficial effects of adenosine during reperfusion following prolonged cardioplegic arrest. Cardiovasc Res 24:247-53.nLe Houerou D, Singh AI, Romano M, et al. 1992. Minimal hemodilution and optimal potassium use during normothermic aerobic arrest. Ann Thorac Surg 54:815-6.nLichtenstein SV, Ashe KA, el Dalati HE, et al. 1991. Warm heart surgery. J Thorac Cardiovasc Surg 101:269-74.nLichtenstein SV, Salerno TA, Slutsky AS. 1990. Pro: warm continuous cardioplegia is preferable to intermittent hypothermic cardioplegia for myocardial protection during cardiopulmonary bypass. J Cardiothorac Anesth 4:279-81.nYoneyama F, Aihara K, Kogi K, et al. 1999. Similarity and dissimilarity in mode and mechanism of action between YT-146, a selective adenosine receptor A agonist, and adenosine in isolated canine hearts. Tohoku J Exp Med 188:31-45.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).